Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC

Head and Neck Cancer Clinical Trial

Official title:

A Randomised Phase II/III Study of Concurrent Cisplatin-Radiotherapy With or Without Induction Chemotherapy Using Gemcitabine, Carboplatin and Paclitaxel in Locally Advanced Nasopharyngeal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00997906
• Other study ID #: CDR0000657121
• Secondary ID: SINGAPORE-NCC090
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: September 15, 2009
• Est. completion date: December 31, 2023

Study information

• Verified date: September 2022
• Source: National Cancer Centre, Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine hydrochloride, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy my kill more tumor cells. It is not yet known whether giving cisplatin together with radiation therapy is more effective with or without gemcitabine hydrochloride, carboplatin, and paclitaxel in treating patients with nasopharyngeal cancer. PURPOSE: This randomized phase II/III trial is studying how well giving cisplatin together with radiation therapy works compared with giving cisplatin and radiation therapy together with gemcitabine hydrochloride, carboplatin, and paclitaxel in treating patients with locally advanced nasopharyngeal cancer.

Description:

OBJECTIVES: Primary - To compare the 5-year overall survival of patients with locally advanced nasopharyngeal cancer treated with concurrent cisplatin and radiotherapy with vs without induction chemotherapy comprising gemcitabine hydrochloride, carboplatin, and paclitaxel. Secondary - To assess and compare the disease-free survival, distant metastases rate, toxicities, and quality of life of patients treated with these regimens. OUTLINE: Patients are stratified by N-stage (N0-1 vs N2-3) and are randomized to 1 of 2 treatment arms. - Arm I: Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions). - Arm II: Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I. Quality of life is assessed periodically. After completion of study treatment, patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 172
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Patients are eligible for inclusion if all of the following criteria are fulfilled:

1. Have given written informed consent, with the understanding that consent may be withdrawn at any time without prejudice.

2. Loco-regional advanced NPC UICC (1997) Stages T3 - 4 any N, or any Stage T, N2 - 3.

3. A histological diagnosis of WHO Type II or III NPC must have been established at some time and the investigator must review and confirm the diagnosis prior to randomization.

4. No evidence of distant metastases in staging work up (including lung, liver and bone imaging).

5. Cross sectional imaging of the primary and neck disease (MRI preferred)

6. Evaluable disease must be present.

7. Performance status of ECOG grade 0 or 1 (see Appendix I).

8. No prior tumour therapy

9. Adequate bone marrow, renal and hepatic function:

Bone marrow : WBC > 3000 / mm3 (ANC > 1500 / mm3 ),

• Platelets > 100 000 / mm3,
• Hb > 10 gm/dl Renal : serum creatinine within institutional normal range (or) lower than the lower limit of institutional normal range
• calculated creatinine clearance > 50 ml / min Hepatic : enzymes (SAP, SGOT) < 2x normal
• bilirubin < 24 µmol / l.

10. At least 18 years of age, of either sex. Exclusion criteria:

Patients are to be excluded from the study if any of the following criteria is fulfilled:

1. Uncontrolled hypercalcaemia: calcium = 2.7 mmol/L (10.8 mg/dL).

2. Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin).

3. Other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).

4. Have serious active infection.

5. Hepatitis B carrier

6. Prior treatment including chemotherapy or radiotherapy.

7. Pregnant or lactating female subjects and subjects with reproductive potential not implementing adequate contraceptive measures.

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• carboplatin,
Given IV
• cisplatin
Given IV
• gemcitabine hydrochloride
Given IV
• paclitaxel
Given IV

Radiation:
• intensity-modulated radiation therapy
Given once daily 5 days a week for 6½ weeks.

Locations

Country	Name	City	State
Singapore	National Cancer Centre - Singapore	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Centre, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival at 5 years		5 years
Secondary	Metastases-free survival		10 years
Secondary	Disease-free survival		10 years
Secondary	Tumor recurrence		10 years
Secondary	Toxicity according to the Common Toxicity Criteria		10 years
Secondary	Quality of life as measured by the EORTC QLQ-C30		5 years